MARKET

AKBA

AKBA

Akebia Therapeut
NASDAQ
1.550
+0.040
+2.65%
Closed 19:11 02/11 EST
OPEN
1.530
PREV CLOSE
1.510
HIGH
1.560
LOW
1.450
VOLUME
4.50M
TURNOVER
0
52 WEEK HIGH
4.079
52 WEEK LOW
1.300
MARKET CAP
411.32M
P/E (TTM)
-20.3947
1D
5D
1M
3M
1Y
5Y
1D
Akebia’s Praliciguat FSGS Trial Moves Forward, Adding Optionality to the Kidney Pipeline
TipRanks · 1d ago
Weekly Report: what happened at AKBA last week (0202-0206)?
Weekly Report · 2d ago
Breaking Down Akebia Therapeutics: 4 Analysts Share Their Views
Benzinga · 5d ago
Akebia Therapeutics Price Target Cut to $4.00/Share From $6.00 by Piper Sandler
Dow Jones · 5d ago
Akebia Therapeutics Is Maintained at Overweight by Piper Sandler
Dow Jones · 5d ago
Piper Sandler Maintains Overweight on Akebia Therapeutics, Lowers Price Target to $4
Benzinga · 5d ago
Akebia Therapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
Dow Jones · 5d ago
HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $6 Price Target
Benzinga · 5d ago
More
About AKBA
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Its HIF-based product candidates and other pipeline assets are being evaluated to target areas of unmet needs. Its product candidates include AKB-9090, AKB-10108, AKB-097 and praliciguat.

Webull offers Akebia Therapeutics Inc stock information, including NASDAQ: AKBA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKBA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKBA stock methods without spending real money on the virtual paper trading platform.